AUA University

Dr. Evan Yu

Claim this profile

Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington

Studies Bladder Cancer
Studies Transitional Cell Carcinoma
5 reported clinical trials
14 drugs studied

Area of expertise

1

Bladder Cancer

Evan Yu has run 3 trials for Bladder Cancer. Some of their research focus areas include:

Stage III
HER2 positive
Stage IV
2

Transitional Cell Carcinoma

Evan Yu has run 3 trials for Transitional Cell Carcinoma. Some of their research focus areas include:

Stage III
HER2 positive
Stage IV

Affiliated Hospitals

Image of trial facility.

Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University Of Washington

Image of trial facility.

Seattle Cancer Care Alliance / University Of Washington

Clinical Trials Evan Yu is currently running

Image of trial facility.

PSMA PET Scan-Directed Therapy

for Prostate Cancer

This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.

Recruiting

1 award

Phase 2

17 criteria

Image of trial facility.

Disitamab Vedotin + Pembrolizumab vs Chemotherapy

for Bladder Cancer

This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.

Recruiting

2 awards

Phase 3

More about Evan Yu

Clinical Trial Related

5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Evan Yu has experience with

  • Disitamab Vedotin
  • Pembrolizumab
  • Abiraterone
  • Abiraterone Acetate
  • Prednisone
  • PSMA PET Scan

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Evan Yu specialize in?

Is Evan Yu currently recruiting for clinical trials?

Are there any treatments that Evan Yu has studied deeply?

What is the best way to schedule an appointment with Evan Yu?

What is the office address of Evan Yu?

Is there any support for travel costs?